Kirsten Craven

Advancing bioanalysis with SCIEX: Insights from three decades of innovation

Feb 18, 2026 | Biopharma, Blogs, Pharma | 0 comments

Read time: 3 minutes

For decades, SCIEX has been part of bioanalytical innovation, empowering scientists in pharma and biopharma to push the boundaries of sensitivity, accuracy, and throughput. Across complex workflows and increasingly challenging therapeutic modalities.

Today, we’re spotlighting three peer‑reviewed publications, spanning nearly thirty years, that reflect how the scientific community continues to innovate. From oligonucleotide quantitation to protein bioanalysis, these studies highlight the evolution in the field and the long-term partnerships we value.

2007: Strategies for Bioanalysis of an Oligonucleotide Class Macromolecule from Rat Plasma Using Liquid Chromatography−Tandem Mass Spectrometry

Publication: 🔗 https://pubs.acs.org/doi/full/10.1021/ac0618674

The study showcased how thoughtful chromatographic design, structured optimization, and careful attention to matrix effects could deliver reliable quantitation even in challenging biological samples. Many of the best practices introduced here, including instrument stability, ionization efficiency, and systematic validation, still underpin quantitative workflows today.

Abstract

Electrospray ionization (ESI) liquid chromatography−tandem mass spectrometry (LC/MS/MS) assays provide high-throughput and selective methods for quantitation of small molecules. Use of LC/MS/MS assays for macromolecules, like oligonucleotides, is challenging due to lack of sensitivity and low analyte recovery from biomatrixes. Due to this fact, the method of choice for oligonucleotides quantitation remains hybridization-based ligand-binding assays…

2014: A Novel and Cost Effective Method of Removing Excess Albumin from Plasma/Serum Samples and Its Impacts on LC-MS/MS Bioanalysis of Therapeutic Proteins

Publication: 🔗 https://pubs.acs.org/doi/full/10.1021/ac501837t

This publication introduced an innovative, cost-effective approach for protein depletion using combinations of organic solvents and acids, validated through signature peptide monitoring. The result? Cleaner extracts, improved sensitivity, and greater confidence in LC–MS/MS quantitation of therapeutic proteins.

Abstract

2024: Bioanalysis of free antisense oligonucleotide payload from antibody–oligonucleotide conjugate by hybridization LC-MS/MS

Publication: 🔗 https://www.tandfonline.com/doi/full/10.1080/…

This 2024 publication captures the cutting edge: hybridization‑based LC–MS/MS approach to measure trace levels of free antisense oligonucleotide payload in complex biological matrices. It demonstrates how advanced workflows, combining sample prep with sensitive mass spectrometry, are enabling scientists to tackle the challenges of next‑generation modalities.

Abstract

We have developed an innovative method to remove albumin from plasma/serum samples for the LC-MS/MS quantitation of therapeutic proteins. Different combinations of organic solvents and acids were screened for their ability to remove albumin from plasma and serum samples. Removal efficiency was monitored by two signature peptides (QTALVELVK and LVNEVTEFAK) from albumin. Isopropanol with 1.0% trichloroacetic acid was found to be the most effective combination to remove albumin while retaining the protein of interest. Our approach was compared with a commercial albumin depletion kit on both efficiency of albumin removal and recovery of target proteins…

Continuous innovation – Driven by scientists, evolving with SCIEX

Each decade has brought new questions and new scientific ingenuity to the forefront. And through it all, SCIEX solutions and partnerships have helped researchers stay ahead of the curve.

As therapeutic innovation accelerates, bioanalysis will continue to evolve. Modalities will diversify. Performance expectations will rise. Workflows will become more hybrid, more integrated, and more data‑driven. SCIEX is committed to supporting scientists on that journey with tools designed not just for today’s challenges, but for tomorrow’s discoveries.

Ready to advance your bioanalysis workflows further?

Explore SCIEX Bioanalysis & DMPK Applications pages >

Discover solutions, workflows, and technical insights designed to help you push sensitivity, accelerate method development, and solve complex quantitation challenges.

Join the BioA Collective on LinkedIn >

Connect with a global community of bioanalytical scientists, share expertise, and stay inspired by real‑world innovation.

Why SCIEX partners with experts around the world

Innovation in mass spectrometry does not happen in isolation. Some of the most impactful scientific advances emerge from highly specialized research communities – proteomics experts developing new peptide identification workflows, metabolomics researchers curating spectral databases, toxicologists building compound libraries, and biopharma scientists creating novel characterization methods.

Managing ADC characterization: The challenge of turning complexity into confidence

Unlike traditional monoclonal antibodies, ADCs combine an antibody backbone with linker chemistry and a cytotoxic payload. This multi-component architecture introduces overlapping layers of heterogeneity, including drug-to-antibody ratio (DAR) distributions, charge variants, post-translational modifications, and structural changes at both the intact and subunit levels. Across ADC development, these characteristics are considered critical quality attributes that must be characterized, understood, and monitored.

3 reasons ZT Scan DIA is changing the game in metabolomics

For years, metabolomics researchers have faced a frustrating reality: modern high-resolution mass spectrometers can detect tens of thousands of molecular features, yet only a fraction can be confidently identified. The challenge is no longer finding molecules. It is generating the high-quality MS/MS data needed to confidently assign structures and extract meaningful biological insights.

Posted by

Kirsten Craven

Kirsten Craven is the Senior Global Marketing Manager for Pharma global strategic marketing at SCIEX. In this role, she manages strategic marketing for the pharmaceutical industry. Kirsten spent the first part of her career working in laboratories across multiple industries before moving into product management, and most recently pharma marketing.

0 Comments